Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer.
Zurlo IV, Schino M, Strippoli A, Calegari MA, Cocomazzi A, Cassano A, Pozzo C, Di Salvatore M, Ricci R, Barone C, Bria E, Tortora G, Larocca LM, Basso M, Martini M. Zurlo IV, et al. Cancer Immunol Immunother. 2022 Jan;71(1):45-55. doi: 10.1007/s00262-021-02960-1. Epub 2021 May 19. Cancer Immunol Immunother. 2022. PMID: 34009410 Free PMC article.
The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases.
Basso M, Corallo S, Calegari MA, Zurlo IV, Ardito F, Vellone M, Marchesani S, Orlandi A, Dadduzio V, Fucà G, Di Dio C, Mele C, Barbaro B, Strippoli A, Coppola A, Cassano A, Bria E, Barone CA, Giuliante F. Basso M, et al. Among authors: zurlo iv. Sci Rep. 2020 Jul 2;10(1):10871. doi: 10.1038/s41598-020-67676-1. Sci Rep. 2020. PMID: 32616782 Free PMC article.
Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study).
Calegari MA, Salvatore L, Di Stefano B, Basso M, Orlandi A, Boccaccino A, Lombardo F, Auriemma A, Zurlo IV, Bensi M, Camarda F, Ribelli M, Vivolo R, Cocomazzi A, Pozzo C, Milella M, Martini M, Bria E, Tortora G. Calegari MA, et al. Among authors: zurlo iv. Cancers (Basel). 2021 Apr 27;13(9):2098. doi: 10.3390/cancers13092098. Cancers (Basel). 2021. PMID: 33925278 Free PMC article.
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study.
Parisi A, Cortellini A, Cannita K, Venditti O, Camarda F, Calegari MA, Salvatore L, Tortora G, Rossini D, Germani MM, Boccaccino A, Dell'Aquila E, Fulgenzi C, Santini D, Tursi M, Tinari N, Marino PD, Lombardi P, Keränen SR, Álvaro MH, Zurlo IV, Corsi DC, Emiliani A, Zanaletti N, Troiani T, Vitale P, Giampieri R, Merloni F, Occhipinti MA, Marchetti P, Roberto M, Mazzuca F, Ghidini M, Indini A, Garajova I, Zoratto F, Monache SD, Porzio G, Ficorella C. Parisi A, et al. Among authors: zurlo iv. Cancers (Basel). 2020 May 16;12(5):1259. doi: 10.3390/cancers12051259. Cancers (Basel). 2020. PMID: 32429380 Free PMC article.
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis.
Parisi A, Giampieri R, Mammarella A, Felicetti C, Salvatore L, Bensi M, Maratta MG, Strippoli A, Filippi R, Satolli MA, Petrillo A, Daniele B, De Tursi M, Di Marino P, Giordano G, Landriscina M, Vitale P, Zurlo IV, Dell'Aquila E, Tomao S, Depetris I, Di Pietro FR, Zoratto F, Ciardiello D, Pensieri MV, Garrone O, Galassi B, Ferri C, Berardi R, Ghidini M. Parisi A, et al. Among authors: zurlo iv. Front Oncol. 2022 Aug 12;12:935826. doi: 10.3389/fonc.2022.935826. eCollection 2022. Front Oncol. 2022. PMID: 36033477 Free PMC article.
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study.
Parisi A, Cortellini A, Venditti O, Filippi R, Salvatore L, Tortora G, Ghidini M, Nigro O, Gelsomino F, Zurlo IV, Fulgenzi C, Lombardi P, Roselló Keränen S, Depetris I, Giampieri R, Morelli C, Di Marino P, Di Pietro FR, Zanaletti N, Vitale P, Garajova I, Spinelli GP, Zoratto F, Roberto M, Petrillo A, Aimar G, Patruno L, D'Orazio C, Ficorella C, Ferri C, Porzio G. Parisi A, et al. Among authors: zurlo iv. Front Oncol. 2021 Oct 27;11:712053. doi: 10.3389/fonc.2021.712053. eCollection 2021. Front Oncol. 2021. PMID: 34778029 Free PMC article.
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
Antonetti P, Fargnoli MC, Porzio G, Salvatore L, Filippi R, Ghidini M, Nigro O, Gelsomino F, Zurlo IV, Dell'Aquila E, Lombardi P, Keränen SR, Depetris I, Giampieri R, Morelli C, De Tursi M, Di Pietro FR, Zanaletti N, Vitale P, Garajova I, Spinelli GP, Zoratto F, Roberto M, Petrillo A, Aimar G, Cortellini A, Pensieri MV, Ficorella C, Ferri C, Parisi A. Antonetti P, et al. Among authors: zurlo iv. Support Care Cancer. 2022 Mar;30(3):2455-2465. doi: 10.1007/s00520-021-06652-5. Epub 2021 Nov 15. Support Care Cancer. 2022. PMID: 34779921
Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis.
Basso M, Signorelli C, Calegari MA, Lucchetti J, Zurlo IV, Dell'Aquila E, Arrivi G, Zoratto F, Santamaria F, Saltarelli R, Trovato G, Caira G, Angotti L, Schirripa M, Anghelone A, Schietroma F, Chilelli MG, Salvatore L, Pozzo C, Tortora G. Basso M, et al. Among authors: zurlo iv. Target Oncol. 2024 Apr 13. doi: 10.1007/s11523-024-01050-3. Online ahead of print. Target Oncol. 2024. PMID: 38613732
18 results